Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris

Thrombosis Journal

Mustafa Akin³  Azem Akilli³  Emil Aliyev⁴  Cevad Sekuri²  Istemihan Tengiz⁴  Huseyin Bozdemir¹  Ertugrul Ercan⁴ 

[1] Cardiology Department, Buca SSK Hospital, Buca/Izmir, Turkey;Cardiology Department, Kent Hospital, Cigli/Izmir, Turkey;Cardiology Department, Ege University Medical School, 35100 Bornova/Izmir, Turkey;Cardiology Department, Central Hospital, 1644 Sk No:2/2 35010 Bayrakli/Izmir, Turkey

关键词: Cell adhesion molecules;    Inflammation;    GP IIb/IIIa antagonists;    Unstable angina pectoris;   

Others  :  839934
DOI  :  10.1186/1477-9560-2-4

 received in 2003-10-06, accepted in 2004-04-01,  发布年份 2004

【 摘 要 】

Aim

The inflammatory response, initiated by neutrophil and monocyte adhesion to endothelial cells, is important in the pathogenesis of acute coronary syndromes. Platelets play an important role in inflammatory process by interacting with monocytes and neutrophils. In this study, we investigated the effect of tirofiban on the levels of cell adhesion molecules (soluble intercellular adhesion molecule-1, sICAM-1, and vascular cell adhesion molecule-1, sVCAM-1) in patients with unstable angina pectoris (AP).

Methods

Thirty-five patients with unstable AP (Group I), ten patients with stable AP (Group II) and ten subjects who had angiographycally normal coronary arteries (Group III) were included the study. Group I was divided into two subgroups for the specific treatment regimens: Group IA (n = 15) received tirofiban and Group IB (n = 20) did not. Blood samples for investigating the cell adhesion molecules were drawn at zero time (baseline; 0 h) in all patients and at 72 h in Group I.

Results

The baseline levels of sICAM-1 and sVCAM-1 were higher in Group I than in Groups II and III. They were higher in Group IA than in Group IB. However, the sICAM-1 and sVCAM-1 levels decreased significantly in Group IA after tirofiban infusion. In contrast, these levels remained unchanged or were increased above the baseline value in Group IB at 72 h.

Conclusion

The levels of cell adhesion molecules in patients with unstable AP decreased significantly after tirofiban infusion. Inhibition of platelet function by specific glycoprotein IIb/IIIa antagonists may decrease platelet-mediated inflammation and the ischemic end-point.

【 授权许可】

   
2004 Ercan et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Fuster V, Chesebro JH: Mechanism of unstable angina. N Engl J Med 1986, 315:1023-1024.
• [2]Ricevuti G, Mazzone G, Pasotti D, De Servi S, Specchia G: Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991, 91:1-14.
• [3]Buja LM, Willerson JT: Role of inflammation in coronary plaque distruption. Circulation 1994, 89:503-505.
• [4]Rothlein R, Mainolfi EA, Czajkowski M: A form of circulating ICAM-1 in human serum. J Immunol 1991, 147:3788-3793.
• [5]Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, Bramucci E, Angoli L, Marsico F, Specchia G: Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993, 88:358-363.
• [6]Ikeda H, Takajo Y, Ichiki K, Ueno T, Maki S, Noda T, Sugi K, Imaizumi T: Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995, 92:1693-1696.
• [7]Price DT, Loscalzo J: Cellular adhesion molecules and atherogenesis. Am J Med 1999, 107:85-97.
• [8]Bevilacqua MP, Nelson RM, Mannoi G, Cecconi O: Endothelial leukocyte adhesion molecules in human disease. Ann Rev Med 1994, 45:361-378.
• [9]The CAPTURE investigators: Randomized Placebo controlled trial of abciximab before and during coronary intervention in refractor unstable angina. Lancet 1997, 349:1623-1629.
• [10]The PURSUIT investigators: Inhibition of platelet glycoprotein IIb/IIIa receptor with eptifibatide in patients with acute coronary syndromes. N Eng J Med 1998, 339:436-443.
• [11]The PRISM investigators: A comprasion of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Eng J Med 1998, 338:1498-1505.
• [12]The PRISM-PLUS investigators: Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction. N Eng J Med 1998, 338:1488-1497.
• [13]The PARAGON investigators: International, randomized, controlled trial of lamifiban, heparin or both in unstable angina. Circulation 1998, 97:2386-2395.
• [14]Jones A, Geczy CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunology 1990, 71:236-241.
• [15]Lincoff AM, Califf RM, Topol EJ: Platelet glycoprotein IIb/IIIa blockade in coronary artery disease. J Am Coll Cardiol 2000, 35:1103-1115.
• [16]Shebuski RJ, Kilgore KS: Role of inflammatory mediators in thrombogenesis. The Journal of Pharmacology and Experimental Therapeutics 2002, 300:729-735.
• [17]Aukrust P, Weahre T, Damas JK, Gullestad L, Solum NO: Inflammatory role of platelets in acute coronary syndromes. Heart 2001, 86:605-606.
• [18]Freedman JE, Loscalzo J: Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002, 105:2130-2132.
• [19]Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA: Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996, 97:1525-1534.
• [20]Carlos TM, Harlan JM: Leukocyte-endothelial cell adhesion molecules. Blood 1994, 84:2069-2072.
• [21]Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM: The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002, 30:294-301.
• [22]Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, Broekman MJ, Marcus AJ: Platelet-erythrocyte interactions enhance alpha(llb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002, 99:3978-3984.
• [23]Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002, 105:2166-2171.
• [24]O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE: Neovascular expression of E-selectin, intracellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996, 93:672-682.
• [25]Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J: Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials. J Thromb 2002, 14:197-203.
• [26]Ercan E, Tengiz I, Duman C, Onbasili OA, Baris N: The effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. Am Heart J 2004, 147:E1.